Can AI Innovation and CRM Wins Boost Veeva Systems' Q2 Results?

Veeva Systems VEEV is scheduled to report second-quarter fiscal 2027 results on Aug. 26, after the market close.

In the last reported quarter, the company’s earnings per share (EPS) of $2.24 topped the Zacks Consensus Estimate by 5.16%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all four occasions, delivering an earnings surprise of 5.45%, on average.

Let’s check out the factors that have shaped VEEV’s performance prior to this announcement.

Factors to Note Before VEEV Reports Q2 Results

Falcon AI Rollout Remains the Biggest Growth Catalyst: Investors are likely to closely watch management's commentary on Veeva Falcon, which emerged as the company's biggest long-term AI initiative in the first quarter. Management positioned Falcon as an "agentic labor" platform designed to automate high-volume workflows such as clinical trial document processing, safety case triage and regulatory correspondence rather than serving as a traditional AI assistant.

 The company has been rapidly building the platform, onboarding early customers and preparing for its early adopter launch. Investors will look for updates on customer engagement, deployment timelines, pricing strategy and progress toward commercialization, as Falcon represents a significant expansion beyond Veeva's traditional software business.

Vault CRM Momentum and Commercial Execution in Focus: Another key area of focus will be Veeva's continued execution in Commercial Cloud, particularly Vault CRM. In the first quarter, the company secured major global wins with Teva and Merck KGaA, expanded its installed base to more than 150 live customers and completed more than 40 CRM migrations.

Management also reported an overall win rate exceeding 80% while expecting to capture the majority of the remaining Top 20 CRM decisions. Investors will therefore look for additional enterprise wins, migration progress, AI adoption within Vault CRM and further commercialization of new offerings like Commercial Evidence and Ostro, which are expected to have strengthened the company's commercial ecosystem.

R&D Cloud Growth and Crossix Strength to Support Revenue Expansion: Investors will also assess whether Veeva Systems can sustain momentum across its R&D portfolio and Crossix business. During the first quarter, management highlighted healthy growth across Development Cloud and Quality Cloud, supported by early-stage products such as EDC, RTSM, Safety, LIMS and eCOA. At the same time, Crossix continued gaining market share as pharmaceutical companies increased digital marketing spending and expanded measurement across newer channels like OpenEvidence. Investors are likely to watch for updates on enterprise R&D wins, pipeline conversion, Crossix growth durability and continued adoption of newer cloud products, as these businesses remain important drivers of long-term subscription revenue expansion.

Profitability and FY2027 Guidance Will Be Closely Watched: Investors are likely to closely evaluate Veeva Systems' ability to balance continued AI investments with its industry-leading profitability. The company began fiscal 2027 with revenue and operating income exceeding guidance while maintaining that the broader macro environment remains healthy. Management continues investing in Falcon, Vault AI, Data Cloud and services while expecting AI revenue outside Ostro to remain largely immaterial this year. Investors will therefore focus on subscription margins, operating income, cash generation and any changes to full-year guidance, as these metrics will indicate whether Veeva Systems can sustain profitable growth while funding its next phase of innovation.

Veeva Systems Inc. Price and EPS Surprise

Veeva Systems Inc. price-eps-surprise | Veeva Systems Inc. Quote

VEEV’s Estimate Picture

For second-quarter fiscal 2027, the Zacks Consensus Estimate for revenues is pegged at $904.1 million, implying an improvement of 14.6% from the prior-year quarter’s reported figure.

The consensus estimate for EPS is pegged at $2.22, indicating growth of 11.6% from the prior-year period’s reported number.

What Our Model Suggests About VEEV

Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.

Earnings ESP: VEEV has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank:The company currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank stocks here.

VEEV’s Share Price Performance

In the year-to-date period, VEEV shares have gained 11.0%, trailing the broader Zacks Medical Information Systems Market, which has advanced 15.4% over the same period.

VEEV has also slightly underperformed the S&P 500, which has returned 11.7%, as investors have balanced enthusiasm around the company's AI-driven innovation with broader healthcare technology market performance.

Among its closest peers, VEEV has marginally outperformed Medpace MEDP, which has gained 10.5%, but trailed IQVIA IQV, whose shares have rallied 15.2% during the same period.

Image Source: Zacks Investment Research

VEEV’s Key Valuation Metric

From a valuation standpoint, VEEV is trading at a forward 12-month price-to-sales (P/S) multiple of 10.38X, reflecting a premium valuation relative to its healthcare technology peers.

The elevated multiple indicates that investors continue assigning a higher valuation to Veeva Systems’ long-term growth prospects, supported by its expanding AI-driven software ecosystem, strong position in life sciences cloud applications and durable recurring revenue model.

VEEV currently trades well above Medpace, which carries a forward 12-month P/S multiple of 5.83X, and IQVIA, which is valued at 2.37X sales.

Image Source: Zacks Investment Research

VEEV’s Long-Term Investment Visibility

Veeva Systems’ long-term investment thesis remains supported by its expanding life sciences cloud ecosystem and growing leadership in industry-specific artificial intelligence. The company continues strengthening its Commercial Cloud and Development Cloud businesses through Vault CRM migrations, Crossix market share gains and expanding adoption of products like Safety, EDC, RTSM and LIMS.

At the same time, management views Falcon as a transformational opportunity that extends Veeva beyond traditional software by introducing AI-powered "agentic labor" for high-volume workflows such as clinical trial document processing and safety case management. These initiatives significantly broaden the company's addressable market while deepening customer engagement across pharmaceutical research and commercialization.

Artificial intelligence remains Veeva Systems’ biggest long-term differentiator. Management believes its MAAP (Models, Agents and Applications) architecture, combined with Vault AI and Falcon, creates a structural advantage by integrating AI-driven automation with Veeva Systems’ established software and consulting expertise. Early customer adoption of Vault AI agents, continued investments in Falcon's rollout and the strategic expansion of Ostro strengthen the company's long-term revenue visibility while supporting management's broader objective of delivering greater value to life sciences customers through increasingly integrated AI-powered solutions.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research